Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:Q9UIJ5 (
Rec
)
58,342
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The activity of alpha-(
2,4-dichlorophenyl
)-beta,N-imidazolylethyl 4-phenylthiobenzyl ether nitrate (fenticonazole,
Rec
15/1476) compared with those of reference drugs, was tested in vitro on various bacteria and fungi. This compound showed in vitro an excellent activity against gram-positive microorganisms. The antifungal activity spectrum is very broad: dermatophytes, yeasts and dimorphic fungi were the most susceptible organisms. Fenticonazole showed in vitro at pH range 4-5 the highest activity against yeasts. The addition of inactivated bovine serum to the culture medium led to a slight decrease in activity of all the tested substances.
...
PMID:Fenticonazole, a new imidazole derivative with antibacterial and antifungal activity. In vitro study. 719 13
The antifungal activity of alpha-(
2,4-dichlorophenyl
)-beta,N-imidazolylethyl 4-phenylthiobenzyl ether nitrate (fenticonazole,
Rec
15/1476) in experimental dermatomycosis and candidiasis in guinea pigs was studied. Fenticonazole proved to be a very active drug with a healing capacity generally higher than that of the reference compounds. The adequate range of activity was from 1% to 3%, giving complete healing without relapses in 100% of cases treated. Fenticonazole is presently undergoing further experimental studies and on the basis of our results a clinical trial would therefore seem to be essential.
...
PMID:Antifungal activity of fenticonazole in experimental dermatomycosis and candidiasis. 719 14
The forward mutational assay on Schizosaccharomyces pombe and the mitotic gene conversion assay on Saccharomyces cerevisiae were performed in order to verify whether alpha-(
2,4-dichlorophenyl
)-beta,N-imidazolylethyl 4-phenylthiobenzyl ether nitrate (fenticonazole,
Rec
15/1476) shows a potential mutagenicity. In both tests the drug does not seem to possess any mutagenic activity when compared with mutagenic standards.
...
PMID:Mutagenicity studies on fenticonazole, a new antifungal imidazole derivative. 719 15
The acute oral and subchronic (6 weeks) topical toxicity of alpha-(
2,4-dichlorophenyl
)-beta,N-imidazolylethyl 4-phenylthiobenzyl ether nitrate (fenticonazole,
Rec
15/1476) was studied in mice, rats, guinea pigs and beagle dogs. The acute oral LD50 in mice and rats was found to be 3000 mg/kg, while the i.p. acute toxicity was 1191 mg/kg in mice and between 309 and 440 mg/kg in rats. The acute oral LD50 in beagle dogs was 1000 mg/kg. Percutaneous subchronic (6 weeks) toxicity was evaluated in guinea pigs and beagle dogs. Both species of animals exhibited no toxic effect attributable to the treatment with fenticonazole and no histopathologic changes were attributed to the drug treatment. Fenticonazole did not affect numerous pharmacological and physiological parameters (blood pressure, heart rate, pulmonary ventilation, nor did it interfere with the activity of histamine, adrenaline, noradrenaline and acetylcholine). It does not possess analgesic or antiinflammatory activity at high doses (100 mg/kg p.o.). In mice it exhibits a slight CNS depressant activity, milder than that of miconazole.
...
PMID:Toxicological and pharmacological properties of fenticonazole, a new topical antimycotic. 719 16
Various tests were used in order to ascertain any irritating, sensitising or toxic potential of alpha-(
2,4-dichlorophenyl
)-beta,N-imidazolylethyl 4-phenylthiobenzyl ether nitrate (fenticonazole,
Rec
15/1476) when applied to the skin or to mucous membranes in gel or cream formulation. When instilled into the conjunctival sac in rabbits fenticonazole led to a slight reddening of the mucosa in only one animal. The reddening appeared 1 h after treatment and disappeared within 24 h. Guinea pigs topically treated for 20 days with fenticonazole 2% gel or cream showed mild erythema which appeared 5 days after the beginning of the treatment and virtually disappeared at the end of the treatment. The treatment with fenticonazole 2% gel or cream did not induce sensitisation. Fenticonazole was not phototoxic or photosensitising when a 2% gel or cream formulation was applied topically to guinea pigs, at the dosage of 0.1 ml per animal.
...
PMID:Irritation and toxicity studies with fenticonazole applied topically to the skin and mucous membranes. 719 17